This study evaluated the impact of the interval between diagnosis and surgery on mortality in patients with early-stage non-small cell lunger cancer (NSCLC).
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Lung - Cancer
June 26, 2025
This study investigates the prognostic impact of tumor spread through air spaces (STAS) in early-stage synchronous multiple primary lung adenocarcinoma (sMPLA) and its interaction with surgical strategies. Among 131 patients with cT1-3N0M0 sMPLA, STAS was detected in 52 percent, including 16 percent with STAS in both tumors (bi-STAS).
June 26, 2025
This study evaluated the effect of perioperative invasive nodal staging on nodal upstaging in early-stage non-small cell lung cancer (NSCLC) patients undergoing resection.
Safety and Feasibility of Novel Single-Port Robotic-Assisted Lobectomy/Segmentectomy for Lung Cancer
June 5, 2025
This study evaluated the SHURUI single-port (SP) robotic system for uniportal robotic-assisted thoracic surgery (RATS) in lung cancer patients.
June 5, 2025
This article discusses a promising diagnostic approach aimed at improving patient selection for immune checkpoint inhibitor (ICI) therapies, particularly in non-small cell lung cancer (NSCLC). The current reliance on PD-L1 immunohistochemistry (IHC) as a biomarker has limited sensitivity and specificity.
June 5, 2025
This article reviews recent efforts to evaluate the use of osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), in the neoadjuvant setting for patients with resectable EGFR-mutant non-small cell lung cancer (NSCLC).
May 7, 2025
This retrospective analysis compared three-port and four-port robotic-assisted thoracoscopic surgery (RATS) lobectomy for non-small cell lung cancer (NSCLC)(n=121, 2020–2021). Demographics, tumor characteristics, complications, and lymph node yields were similar between groups.
May 1, 2025
Extended sleeve lobectomy (ESL) is considered a lung-sparing alternative to pneumonectomy (PN) for centrally located non-small cell lung cancer (NSCLC) when standard sleeve lobectomy (SSL) is not feasible. This retrospective study analyzed 94 patients who received neoadjuvant immunochemotherapy followed by either PN, ESL, or SSL.
May 1, 2025
The recent CheckMate 816 trial indicated that neoadjuvant chemo-immunotherapy provided limited local control in stage II–III resectable non-small cell lung cancer (NSCLC).
April 17, 2025
This article presents a comprehensive epidemiological analysis of lung cancer, focusing on subtype-specific patterns worldwide.